Alvotech (NASDAQ:ALVO – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.50, Zacks reports.
Alvotech Stock Down 0.9 %
Shares of NASDAQ:ALVO traded down $0.11 during trading on Wednesday, hitting $11.55. 96,280 shares of the company were exchanged, compared to its average volume of 136,383. The company has a market capitalization of $3.48 billion, a P/E ratio of -6.24 and a beta of -0.16. Alvotech has a 1-year low of $9.15 and a 1-year high of $14.76. The business’s 50 day moving average is $12.14 and its 200-day moving average is $12.18.
Wall Street Analysts Forecast Growth
Separately, UBS Group initiated coverage on Alvotech in a research note on Friday, February 14th. They set a “buy” rating and a $18.00 target price for the company.
Alvotech Company Profile
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.
Featured Articles
- Five stocks we like better than Alvotech
- Differences Between Momentum Investing and Long Term Investing
- Energy Transfer: Powering Data With Dividends and Diversification
- Investing in the High PE Growth Stocks
- Qualcomm Stock Is Coiling for a Breakout
- Best Stocks Under $10.00
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for Alvotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alvotech and related companies with MarketBeat.com's FREE daily email newsletter.
